Atomic structure of a thermostable subdomain of HIV-1 gp41.

Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol (2000) 6.71

Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci U S A (1998) 4.34

N- and C-terminal residues combine in the fusion-pH influenza hemagglutinin HA(2) subunit to form an N cap that terminates the triple-stranded coiled coil. Proc Natl Acad Sci U S A (1999) 3.90

Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J (1998) 3.77

The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol (2003) 3.71

Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol (2002) 3.59

Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus. J Virol (2000) 3.52

Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-A resolution. Proc Natl Acad Sci U S A (1999) 3.23

The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev (2008) 3.16

Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J Virol (2002) 2.91

Mapping of functional elements in the stem-anchor region of tick-borne encephalitis virus envelope protein E. J Virol (1999) 2.87

Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol (2005) 2.86

Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins. J Virol (2000) 2.86

N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob Agents Chemother (2004) 2.76

Structural characterization of the human respiratory syncytial virus fusion protein core. Proc Natl Acad Sci U S A (2000) 2.58

Crystal structure of the simian immunodeficiency virus (SIV) gp41 core: conserved helical interactions underlie the broad inhibitory activity of gp41 peptides. Proc Natl Acad Sci U S A (1998) 2.46

Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci U S A (2004) 2.44

Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J Virol (2001) 2.38

Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J Virol (2001) 2.38

Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog (2009) 2.34

Crystal structure of human T cell leukemia virus type 1 gp21 ectodomain crystallized as a maltose-binding protein chimera reveals structural evolution of retroviral transmembrane proteins. Proc Natl Acad Sci U S A (1999) 2.32

Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. Proc Natl Acad Sci U S A (2001) 2.20

Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution. J Virol (2000) 2.15

A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. J Virol (1998) 2.12

Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J Virol (2002) 2.06

Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer. Proc Natl Acad Sci U S A (2013) 2.05

Stoichiometry of envelope glycoprotein trimers in the entry of human immunodeficiency virus type 1. J Virol (2005) 2.05

HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol (2011) 2.01

Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. J Virol (1999) 1.89

Structural and biological mimicry of protein surface recognition by alpha/beta-peptide foldamers. Proc Natl Acad Sci U S A (2009) 1.87

Dissection of human immunodeficiency virus type 1 entry with neutralizing antibodies to gp41 fusion intermediates. J Virol (2002) 1.79

Short constrained peptides that inhibit HIV-1 entry. Proc Natl Acad Sci U S A (2002) 1.77

Potent D-peptide inhibitors of HIV-1 entry. Proc Natl Acad Sci U S A (2007) 1.76

Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat Med (2015) 1.74

Mutational analysis of residues in the coiled-coil domain of human immunodeficiency virus type 1 transmembrane protein gp41. J Virol (1998) 1.69

Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins. J Virol (2002) 1.65

Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor. J Virol (2004) 1.64

Functional importance of the coiled-coil of the Ebola virus glycoprotein. J Virol (2000) 1.59

Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. J Virol (2004) 1.58

The central structural feature of the membrane fusion protein subunit from the Ebola virus glycoprotein is a long triple-stranded coiled coil. Proc Natl Acad Sci U S A (1998) 1.58

Envelope glycoprotein determinants of increased fusogenicity in a pathogenic simian-human immunodeficiency virus (SHIV-KB9) passaged in vivo. J Virol (2000) 1.55

Inhibiting HIV fusion with a beta-peptide foldamer. J Am Chem Soc (2005) 1.55

Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. J Virol (2002) 1.54

The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle. J Virol (2005) 1.53

Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1. J Virol (2004) 1.51

Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity. PLoS Pathog (2011) 1.47

Effects of the I559P gp41 change on the conformation and function of the human immunodeficiency virus (HIV-1) membrane envelope glycoprotein trimer. PLoS One (2015) 1.46

Crystallization of a trimeric human T cell leukemia virus type 1 gp21 ectodomain fragment as a chimera with maltose-binding protein. Protein Sci (1998) 1.45

Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys. J Virol (2001) 1.40

Coevolution Analysis of HIV-1 Envelope Glycoprotein Complex. PLoS One (2015) 1.39

Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d. J Virol (2004) 1.38

Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding. J Virol (2010) 1.38

Structural and functional analysis of interhelical interactions in the human immunodeficiency virus type 1 gp41 envelope glycoprotein by alanine-scanning mutagenesis. J Virol (2001) 1.38

Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proc Natl Acad Sci U S A (2010) 1.36

Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection. Proc Natl Acad Sci U S A (2005) 1.36

Localized changes in the gp120 envelope glycoprotein confer resistance to human immunodeficiency virus entry inhibitors BMS-806 and #155. J Virol (2004) 1.35

Interaction of peptides with sequences from the Newcastle disease virus fusion protein heptad repeat regions. J Virol (1999) 1.34

Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding. J Virol (2002) 1.33

Design of a potent D-peptide HIV-1 entry inhibitor with a strong barrier to resistance. J Virol (2010) 1.33

Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion. J Virol (2002) 1.30

Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus. J Virol (2001) 1.29

The core of the respiratory syncytial virus fusion protein is a trimeric coiled coil. J Virol (2000) 1.29

Subunit stoichiometry of human immunodeficiency virus type 1 envelope glycoprotein trimers during virus entry into host cells. J Virol (2006) 1.26

Peptides corresponding to the heptad repeat motifs in the transmembrane protein (gp41) of human immunodeficiency virus type 1 elicit antibodies to receptor-activated conformations of the envelope glycoprotein. J Virol (2001) 1.26

Peptide ligands to human immunodeficiency virus type 1 gp120 identified from phage display libraries. J Virol (1999) 1.24

Solid-state NMR spectroscopy of human immunodeficiency virus fusion peptides associated with host-cell-like membranes: 2D correlation spectra and distance measurements support a fully extended conformation and models for specific antiparallel strand registries. J Am Chem Soc (2008) 1.23

Bluetongue virus coat protein VP2 contains sialic acid-binding domains, and VP5 resembles enveloped virus fusion proteins. Proc Natl Acad Sci U S A (2010) 1.22

Inhibition of human immunodeficiency virus type 1 infectivity by the gp41 core: role of a conserved hydrophobic cavity in membrane fusion. J Virol (1999) 1.22

Selection of T1249-resistant human immunodeficiency virus type 1 variants. J Virol (2008) 1.21

Peptides in the treatment of AIDS. Curr Opin Struct Biol (2009) 1.21

Sequestering of the prehairpin intermediate of gp41 by peptide N36Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41. J Virol (2008) 1.21

Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope. J Virol (2009) 1.21

Production and characterization of a soluble, active form of Tva, the subgroup A avian sarcoma and leukosis virus receptor. J Virol (1999) 1.21

Structure of the HIV-1 gp41 membrane-proximal ectodomain region in a putative prefusion conformation. Biochemistry (2009) 1.20

Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles. BMC Infect Dis (2002) 1.20

Role of the specific amino acid sequence of the membrane-spanning domain of human immunodeficiency virus type 1 in membrane fusion. J Virol (2005) 1.19

HIV-1 envelope glycoprotein structure. Curr Opin Struct Biol (2013) 1.19

Both neutralization resistance and high infectivity phenotypes are caused by mutations of interacting residues in the human immunodeficiency virus type 1 gp41 leucine zipper and the gp120 receptor- and coreceptor-binding domains. J Virol (1999) 1.18

Subdomain folding and biological activity of the core structure from human immunodeficiency virus type 1 gp41: implications for viral membrane fusion. J Virol (1999) 1.17

HIV fusion peptide and its cross-linked oligomers: efficient syntheses, significance of the trimer in fusion activity, correlation of beta strand conformation with membrane cholesterol, and proximity to lipid headgroups. Biochemistry (2009) 1.17

A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization. Retrovirology (2013) 1.17

Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition. J Virol (2008) 1.16

Functional analysis of the disulfide-bonded loop/chain reversal region of human immunodeficiency virus type 1 gp41 reveals a critical role in gp120-gp41 association. J Virol (2001) 1.15

Structural basis of HIV-1 neutralization by affinity matured Fabs directed against the internal trimeric coiled-coil of gp41. PLoS Pathog (2010) 1.14

Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil. J Biol Chem (2008) 1.14

The trimer-of-hairpins motif in membrane fusion: Visna virus. Proc Natl Acad Sci U S A (2001) 1.13

Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J Virol (2006) 1.13

Conformational flexibility and strand arrangements of the membrane-associated HIV fusion peptide trimer probed by solid-state NMR spectroscopy. Biochemistry (2006) 1.13

Cyclodepsipeptides from marine sponges: natural agents for drug research. Mar Drugs (2010) 1.10

Role of hydrophobic residues in the central ectodomain of gp41 in maintaining the association between human immunodeficiency virus type 1 envelope glycoprotein subunits gp120 and gp41. J Virol (2004) 1.10

Structure-function studies of the self-assembly domain of the human immunodeficiency virus type 1 transmembrane protein gp41. J Virol (2000) 1.10

Functional implications of the human T-lymphotropic virus type 1 transmembrane glycoprotein helical hairpin structure. J Virol (2000) 1.08

An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes. Virology (2010) 1.08

Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1. J Med Chem (2008) 1.07

Role of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process. J Virol (2004) 1.07

Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope. Virology (2007) 1.07

Mutations in the fusion peptide and adjacent heptad repeat inhibit folding or activity of the Newcastle disease virus fusion protein. J Virol (2001) 1.06

Amino acid 36 in the human immunodeficiency virus type 1 gp41 ectodomain controls fusogenic activity: implications for the molecular mechanism of viral escape from a fusion inhibitor. J Virol (2005) 1.05

HIV-1 drug-resistance and drug-dependence. Retrovirology (2007) 1.05

A monoclonal Fab derived from a human nonimmune phage library reveals a new epitope on gp41 and neutralizes diverse human immunodeficiency virus type 1 strains. J Virol (2007) 1.05

The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr (1994) 187.88

Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol (1987) 66.52

Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol (1990) 61.47

Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature (1981) 24.17

Atomic structure of the ectodomain from HIV-1 gp41. Nature (1997) 16.31

Core structure of gp41 from the HIV envelope glycoprotein. Cell (1997) 16.18

Structure of influenza haemagglutinin at the pH of membrane fusion. Nature (1994) 14.61

Functional inactivation of genes by dominant negative mutations. Nature (1987) 13.12

The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem (1987) 11.99

X-ray structure of the GCN4 leucine zipper, a two-stranded, parallel coiled coil. Science (1991) 10.81

A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants. Science (1993) 10.16

Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science (1990) 10.13

Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med (1991) 9.28

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A (1994) 8.48

A spring-loaded mechanism for the conformational change of influenza hemagglutinin. Cell (1993) 8.26

A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res Hum Retroviruses (1989) 7.34

A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol (1995) 7.30

A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci U S A (1992) 5.88

Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol (1995) 5.01

HIV-1 inhibition by a peptide. Nature (1993) 5.01

Tropomyosin coiled-coil interactions: evidence for an unstaggered structure. J Mol Biol (1975) 4.79

Retrovirus envelope domain at 1.7 angstrom resolution. Nat Struct Biol (1996) 4.49

Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120. Proc Natl Acad Sci U S A (1991) 4.40

Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J Virol (1993) 4.19

Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins. J Gen Virol (1990) 3.59

Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity. J Virol (1992) 3.54

Crystal structure of an isoleucine-zipper trimer. Nature (1994) 3.30

A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J Virol (1995) 3.11

Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci U S A (1994) 2.88

The role of human immunodeficiency virus type 1 envelope glycoproteins in virus infection. J Biol Chem (1995) 2.70

A buried polar interaction imparts structural uniqueness in a designed heterodimeric coiled coil. Biochemistry (1995) 2.63

A trimeric subdomain of the simian immunodeficiency virus envelope glycoprotein. Biochemistry (1995) 2.57

Chemokines and HIV-1 second receptors. Confluence of two fields generates optimism in AIDS research. Nat Med (1996) 2.44

Neutralization of HIV-1: a paradox of humoral proportions. FASEB J (1991) 2.41

Secondary structures of proteins and peptides in amphiphilic environments. (A review). Proc Natl Acad Sci U S A (1983) 2.26

Retroviral envelope glycoproteins contain a "leucine zipper"-like repeat. AIDS Res Hum Retroviruses (1990) 2.24

Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein. J Virol (1993) 2.21

The HA2 subunit of influenza hemagglutinin inserts into the target membrane prior to fusion. J Biol Chem (1991) 2.07

Buried polar residues and structural specificity in the GCN4 leucine zipper. Nat Struct Biol (1996) 2.06

The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure. AIDS Res Hum Retroviruses (1995) 1.77

Receptor-mediated activation of immunodeficiency viruses in viral fusion. Science (1991) 1.56

Lipid interactions of the hemagglutinin HA2 NH2-terminal segment during influenza virus-induced membrane fusion. J Biol Chem (1992) 1.53

Native-like and structurally characterized designed alpha-helical bundles. Curr Opin Struct Biol (1995) 1.24

What determines where alpha-helices begin and end? Proc Natl Acad Sci U S A (1993) 1.07

Two partially overlapping antiviral peptides from the external portion of HIV type 1 glycoprotein 41, adjoining the transmembrane region, affect the glycoprotein 41 fusion domain. AIDS Res Hum Retroviruses (1995) 1.00

Cofactors provide the entry keys. HIV-1. Curr Biol (1996) 0.99

Structural analysis of the N- and C-termini in a peptide with consensus sequence. Protein Sci (1995) 0.97

Initial sequencing and analysis of the human genome. Nature (2001) 212.86

The sequence of the human genome. Science (2001) 101.55

The transcriptional landscape of the mammalian genome. Science (2005) 37.63

The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. Bioinformatics (2003) 32.92

Base substitutions, length differences and DNA strand asymmetries in the human G gamma and A gamma fetal globin gene region. Cell (1981) 16.76

Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature (2004) 16.76

Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity (2000) 16.03

Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science (1992) 14.70

Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science (1995) 13.15

Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med (2001) 10.36

Avian flu: H5N1 virus outbreak in migratory waterfowl. Nature (2005) 10.04

Highly pathogenic H5N1 influenza virus infection in migratory birds. Science (2005) 9.64

Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc Natl Acad Sci U S A (2006) 9.26

The genome of the social amoeba Dictyostelium discoideum. Nature (2005) 9.18

Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest (1999) 8.38

fw2.2: a quantitative trait locus key to the evolution of tomato fruit size. Science (2000) 7.91

Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice. Nat Genet (1998) 7.89

A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell (1999) 6.82

Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis. Cell (2000) 6.70

Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke (2001) 6.61

Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature (2001) 6.36

Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science (1999) 6.02

A global profile of germline gene expression in C. elegans. Mol Cell (2000) 5.97

Digital tomosynthesis in breast imaging. Radiology (1997) 5.82

Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr (2001) 5.74

Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. Am J Med (2001) 5.68

Structure of the replicating complex of a pol alpha family DNA polymerase. Cell (2001) 5.26

Separation of caveolae from associated microdomains of GPI-anchored proteins. Science (1995) 5.25

Both corepressor proteins SMRT and N-CoR exist in large protein complexes containing HDAC3. EMBO J (2000) 5.22

Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol Cell (2001) 5.19

Indium phosphide nanowires as building blocks for nanoscale electronic and optoelectronic devices. Nature (2001) 5.09

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol (2009) 5.08

High fertilization and implantation rates after intracytoplasmic sperm injection. Hum Reprod (1993) 5.06

Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol (1999) 4.97

A method for efficient isotopic labeling of recombinant proteins. J Biomol NMR (2001) 4.96

Comparing sequenced segments of the tomato and Arabidopsis genomes: large-scale duplication followed by selective gene loss creates a network of synteny. Proc Natl Acad Sci U S A (2000) 4.90

A critical role for DNA end-joining proteins in both lymphogenesis and neurogenesis. Cell (1998) 4.78

Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke (2001) 4.64

Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J Exp Med (2001) 4.63

Emergence and predominance of an H5N1 influenza variant in China. Proc Natl Acad Sci U S A (2006) 4.49

Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology (2002) 4.45

Genome sequence, comparative analysis, and population genetics of the domestic horse. Science (2009) 4.41

Activation of Arp2/3 complex-mediated actin polymerization by cortactin. Nat Cell Biol (2001) 4.38

Improved stability of Drosophila larval neuromuscular preparations in haemolymph-like physiological solutions. J Comp Physiol A (1994) 4.24

Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci U S A (2000) 4.22

Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science (2013) 4.17

Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology (2000) 4.13

Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry Suppl (1996) 3.99

Anthropogenic warming of Earth's climate system. Science (2001) 3.94

Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst (2001) 3.88

Ultralong single-wall carbon nanotubes. Nat Mater (2004) 3.83

Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implications for nitric oxide signaling. Proc Natl Acad Sci U S A (1996) 3.83

Detection of Norwalk virus in stool by polymerase chain reaction. J Clin Microbiol (1992) 3.82

Quantum annealing with manufactured spins. Nature (2011) 3.81

SURF1, encoding a factor involved in the biogenesis of cytochrome c oxidase, is mutated in Leigh syndrome. Nat Genet (1998) 3.79

Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. J Clin Invest (1996) 3.74

Insights into editing from an ile-tRNA synthetase structure with tRNAile and mupirocin. Science (1999) 3.71

The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia (2008) 3.69

Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene (2009) 3.64

Multiferroic BaTiO3-CoFe2O4 Nanostructures. Science (2004) 3.49

A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia (2007) 3.45

Highly conserved core domain and unique N terminus with presumptive regulatory motifs in a human TATA factor (TFIID). Nature (1990) 3.42

Molecular cloning and characterization of a human eotaxin receptor expressed selectively on eosinophils. J Exp Med (1996) 3.33

MyoD-induced expression of p21 inhibits cyclin-dependent kinase activity upon myocyte terminal differentiation. Mol Cell Biol (1995) 3.32

Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int (2016) 3.30

Developing a prediction rule from automated clinical databases to identify high-risk patients in a large population with diabetes. Diabetes Care (2001) 3.27

A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature (1989) 3.27

Genetic analysis of salt tolerance in arabidopsis. Evidence for a critical role of potassium nutrition. Plant Cell (1998) 3.25

Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry. Am J Clin Nutr (1990) 3.24

The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science (1999) 3.23

Environmental effects on photosynthesis, nitrogen-use efficiency, and metabolite pools in leaves of sun and shade plants. Plant Physiol (1987) 3.23

Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci U S A (1997) 3.19

Epithelial sodium channel regulated by aldosterone-induced protein sgk. Proc Natl Acad Sci U S A (1999) 3.19

The crystal structure of elongation factor G complexed with GDP, at 2.7 A resolution. EMBO J (1994) 3.18

The major facilitator superfamily. J Mol Microbiol Biotechnol (1999) 3.17

The genesis and evolution of H9N2 influenza viruses in poultry from southern China, 2000 to 2005. J Virol (2007) 3.12

Immunocytochemical localization of the vanilloid receptor 1 (VR1): relationship to neuropeptides, the P2X3 purinoceptor and IB4 binding sites. Eur J Neurosci (1999) 3.10

Prediction of body cell mass, fat-free mass, and total body water with bioelectrical impedance analysis: effects of race, sex, and disease. Am J Clin Nutr (1996) 3.06

Properties of hyperpolarization-activated pacemaker current defined by coassembly of HCN1 and HCN2 subunits and basal modulation by cyclic nucleotide. J Gen Physiol (2001) 3.04

Prevalence of diabetes and its risk factors in China, 1994. National Diabetes Prevention and Control Cooperative Group. Diabetes Care (1997) 3.03

Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1. J Biol Chem (1996) 3.01

Acupuncture modulates the limbic system and subcortical gray structures of the human brain: evidence from fMRI studies in normal subjects. Hum Brain Mapp (2000) 2.98

Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine. Int Immunol (1999) 2.96

Metallothionein: an intracellular protein to protect against cadmium toxicity. Annu Rev Pharmacol Toxicol (1999) 2.95

Genetic architecture of a morphological shape difference between two Drosophila species. Genetics (2000) 2.92

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). Ann Oncol (2013) 2.92

New tumor markers: CA125 and beyond. Int J Gynecol Cancer (2005) 2.92

SOS3 function in plant salt tolerance requires N-myristoylation and calcium binding. Plant Cell (2000) 2.91

Cell cycle-regulated phosphorylation of p220(NPAT) by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription. Genes Dev (2000) 2.90

Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol (1995) 2.88

Essential function of Gli2 and Gli3 in the formation of lung, trachea and oesophagus. Nat Genet (1998) 2.87

Synergistic activation of the insulin gene by a LIM-homeo domain protein and a basic helix-loop-helix protein: building a functional insulin minienhancer complex. Genes Dev (1992) 2.86

Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J Neurol Sci (2001) 2.84

Endocrine manifestations of stimulatory G protein alpha-subunit mutations and the role of genomic imprinting. Endocr Rev (2001) 2.84

Structure of Taq polymerase with DNA at the polymerase active site. Nature (1996) 2.84

Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart (2002) 2.83

Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med (1999) 2.82

Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene (2012) 2.82